烏美溴銨/維蘭特羅
 烏美溴銨（上方）和維蘭特羅（下方） | |
| 組成 | |
|---|---|
| 烏美溴銨 | 毒蕈鹼拮抗劑 |
| 維蘭特羅 | 超長效β2激動劑 |
| 臨床資料 | |
| 商品名 | Anoro Ellipta、Laventair Ellipta |
| AHFS/Drugs.com | 專業藥物信息 |
| 核准狀況 | |
| 懷孕分級 |
|
| 給藥途徑 | 吸入給藥 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 識別資訊 | |
| CAS號 | 2446159-58-4 |
| KEGG | |
烏美溴銨/維蘭特羅（英語：umeclidinium bromide/vilanterol；商品名：Anoro Ellipta等），是一種用於治療慢性阻塞性肺病 (COPD) 的固定劑量複方藥物。[4][5]它通過吸入給藥。
最常見的副作用包括上呼吸道感染、尿路感染、咽炎、鼻竇炎、鼻咽炎、頭痛、咳嗽、口咽疼痛、便秘和口乾。[3]
2021年，它是美國第212位最常用處方藥物，處方數量超過200萬張。[6][7]
參考資料[編輯]
- ^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].
- ^ Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC). (emc). 7 October 2019 [29 October 2020].
- ^ 3.0 3.1 Anoro Ellipta EPAR. European Medicines Agency (EMA). 17 September 2018 [28 October 2020]. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Therapeutic Advances in Respiratory Disease. December 2013, 7 (6): 311–9. PMID 24004659. S2CID 5744282. doi:10.1177/1753465813499789.
- ^ FDA Approves Umeclidinium and Vilanterol Combo for COPD. Medscape. 18 December 2013.
- ^ The Top 300 of 2021. ClinCalc. [14 January 2024]. （原始內容存檔於15 January 2024）.
- ^ Umeclidinium; Vilanterol - Drug Usage Statistics. ClinCalc. [14 January 2024].
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 | 這是一篇關於呼吸系統的藥理學小作品。你可以透過編輯或修訂擴充其內容。 |